1147 related articles for article (PubMed ID: 27896469)
1. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
Wagner M; Antunes C; Pietrasz D; Cassinotto C; Zappa M; Sa Cunha A; Lucidarme O; Bachet JB
Eur Radiol; 2017 Jul; 27(7):3104-3116. PubMed ID: 27896469
[TBL] [Abstract][Full Text] [Related]
2. Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.
Marchegiani G; Todaro V; Boninsegna E; Negrelli R; Sureka B; Bonamini D; Salvia R; Manfredi R; Pozzi Mucelli R; Bassi C
Eur Radiol; 2018 Oct; 28(10):4265-4273. PubMed ID: 29679211
[TBL] [Abstract][Full Text] [Related]
3. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.
Ferrone CR; Marchegiani G; Hong TS; Ryan DP; Deshpande V; McDonnell EI; Sabbatino F; Santos DD; Allen JN; Blaszkowsky LS; Clark JW; Faris JE; Goyal L; Kwak EL; Murphy JE; Ting DT; Wo JY; Zhu AX; Warshaw AL; Lillemoe KD; Fernández-del Castillo C
Ann Surg; 2015 Jan; 261(1):12-7. PubMed ID: 25599322
[TBL] [Abstract][Full Text] [Related]
4. CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy.
Jang JK; Byun JH; Kang JH; Son JH; Kim JH; Lee SS; Kim HJ; Yoo C; Kim KP; Hong SM; Seo DW; Kim SC; Lee MG
Eur Radiol; 2021 Feb; 31(2):813-823. PubMed ID: 32845389
[TBL] [Abstract][Full Text] [Related]
5. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm?
Christians KK; Tsai S; Mahmoud A; Ritch P; Thomas JP; Wiebe L; Kelly T; Erickson B; Wang H; Evans DB; George B
Oncologist; 2014 Mar; 19(3):266-74. PubMed ID: 24569947
[TBL] [Abstract][Full Text] [Related]
7. FOLFIRINOX-based neoadjuvant chemoradiotherapy for borderline and locally advanced pancreatic cancer: A pilot study from a tertiary centre.
Pouypoudat C; Buscail E; Cossin S; Cassinotto C; Terrebonne E; Blanc JF; Smith D; Marty M; Dupin C; Laurent C; Dabernat S; Chiche L; Vendrely V
Dig Liver Dis; 2019 Jul; 51(7):1043-1049. PubMed ID: 31000479
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas.
Blazer M; Wu C; Goldberg RM; Phillips G; Schmidt C; Muscarella P; Wuthrick E; Williams TM; Reardon J; Ellison EC; Bloomston M; Bekaii-Saab T
Ann Surg Oncol; 2015 Apr; 22(4):1153-9. PubMed ID: 25358667
[TBL] [Abstract][Full Text] [Related]
9. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma.
Hosein PJ; Macintyre J; Kawamura C; Maldonado JC; Ernani V; Loaiza-Bonilla A; Narayanan G; Ribeiro A; Portelance L; Merchan JR; Levi JU; Rocha-Lima CM
BMC Cancer; 2012 May; 12():199. PubMed ID: 22642850
[TBL] [Abstract][Full Text] [Related]
10. Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-FRENCH, Prospective, Multicentric Cohort.
Pietrasz D; Marthey L; Wagner M; Blanc JF; Laurent C; Turrini O; Raoul JL; Terrebonne E; Hentic O; Trouilloud I; Coriat R; Regenet N; Innominato P; Taieb J; Cunha AS; Bachet JB
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1196-205. PubMed ID: 26271395
[TBL] [Abstract][Full Text] [Related]
11. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience.
Faris JE; Blaszkowsky LS; McDermott S; Guimaraes AR; Szymonifka J; Huynh MA; Ferrone CR; Wargo JA; Allen JN; Dias LE; Kwak EL; Lillemoe KD; Thayer SP; Murphy JE; Zhu AX; Sahani DV; Wo JY; Clark JW; Fernandez-del Castillo C; Ryan DP; Hong TS
Oncologist; 2013; 18(5):543-8. PubMed ID: 23657686
[TBL] [Abstract][Full Text] [Related]
12. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
13. FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies.
Petrelli F; Coinu A; Borgonovo K; Cabiddu M; Ghilardi M; Lonati V; Aitini E; Barni S;
Pancreas; 2015 May; 44(4):515-21. PubMed ID: 25872127
[TBL] [Abstract][Full Text] [Related]
14. Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience.
Nitsche U; Wenzel P; Siveke JT; Braren R; Holzapfel K; Schlitter AM; Stöß C; Kong B; Esposito I; Erkan M; Michalski CW; Friess H; Kleeff J
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1212-20. PubMed ID: 26350368
[TBL] [Abstract][Full Text] [Related]
15. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P
Oncology; 2015; 89(1):37-46. PubMed ID: 25766660
[TBL] [Abstract][Full Text] [Related]
16. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.
Suker M; Beumer BR; Sadot E; Marthey L; Faris JE; Mellon EA; El-Rayes BF; Wang-Gillam A; Lacy J; Hosein PJ; Moorcraft SY; Conroy T; Hohla F; Allen P; Taieb J; Hong TS; Shridhar R; Chau I; van Eijck CH; Koerkamp BG
Lancet Oncol; 2016 Jun; 17(6):801-810. PubMed ID: 27160474
[TBL] [Abstract][Full Text] [Related]
17. Predictors of conversion surgery in patients with pancreatic cancer who underwent neoadjuvant or palliative FOLFIRINOX treatment using baseline and follow-up CT.
Park SJ; Kim JH; Joo I; Han JK
Abdom Radiol (NY); 2021 Oct; 46(10):4765-4778. PubMed ID: 34085090
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability.
Nanda RH; El-Rayes B; Maithel SK; Landry J
J Surg Oncol; 2015 Jun; 111(8):1028-34. PubMed ID: 26073887
[TBL] [Abstract][Full Text] [Related]
19. Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas.
Katz MHG; Ou FS; Herman JM; Ahmad SA; Wolpin B; Marsh R; Behr S; Shi Q; Chuong M; Schwartz LH; Frankel W; Collisson E; Koay EJ; Hubbard JM; Leenstra JL; Meyerhardt J; O'Reilly E;
BMC Cancer; 2017 Jul; 17(1):505. PubMed ID: 28750659
[TBL] [Abstract][Full Text] [Related]
20. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial.
Ghaneh P; Palmer D; Cicconi S; Jackson R; Halloran CM; Rawcliffe C; Sripadam R; Mukherjee S; Soonawalla Z; Wadsley J; Al-Mukhtar A; Dickson E; Graham J; Jiao L; Wasan HS; Tait IS; Prachalias A; Ross P; Valle JW; O'Reilly DA; Al-Sarireh B; Gwynne S; Ahmed I; Connolly K; Yim KL; Cunningham D; Armstrong T; Archer C; Roberts K; Ma YT; Springfeld C; Tjaden C; Hackert T; Büchler MW; Neoptolemos JP;
Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):157-168. PubMed ID: 36521500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
